China's drug regulator approved Zhejiang Hisun Pharmaceutical (SHA:600267) subsidiary Hanhui Pharmaceutical's clinical trial for its Hybomimab atorvastatin calcium tablets, according to a Tuesday disclosure to the Shanghai bourse.
The drug is indicated for patients with high cholesterol levels whose low-density lipoprotein levels could not be achieved with solo statin therapy, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments